Retardation of coronary atherosclerosis: The bezafibrate coronary atherosclerosis intervention trial (BECAIT) and other angiographic trials

Cardiovascular Drugs and Therapy

Volumn 11, Issue SUPPL. 1, 1997, Pages 257-263

  De Faire, Ulf ^a   Ericsson, Carl Göran ^b   Grip, Lars ^a   Nilsson, Jan ^a   Svane, Bertil ^a   Hamsten, Anders ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b DANDERYD HOSPITAL   (Sweden)

Author keywords

BECAIT; Coronary atherosclerosis; LDL cholesterol; Triglyceride rich lipoproteins fibrinogen bezafibrate

Indexed keywords

BEZAFIBRATE; CHOLESTEROL; COLESTIPOL; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ANGIOCARDIOGRAPHY; ARTERY DIAMETER; ARTICLE; ATHEROMA; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DRUG MECHANISM; FIBRINOGEN BLOOD LEVEL; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; META ANALYSIS; METABOLISM; MORTALITY; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ANTILIPEMIC AGENTS; BEZAFIBRATE; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; ENZYME INHIBITORS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 0030905352     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007787713191     Document Type: Article

References (44)

1. Bergstrand R, Vedin A, Wilhelmsson C, Wilhelmsen L. Incidence and prognosis of acute myocardial infarction among men below age 40 in Göteborg, Sweden. Eur Heart J 1982;3:130-135.
2. Hamsten A, Walldius G, Szamosi A, Dahlén G, de Faire U. Relationship of angiographically defined coronary artery disease to serum lipoproteins and apolipoproteins in young survivors of myocardial infarction. Circulation 1986;73:1097-1110.
3. Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young male survivors of myocardial infarction. N Engl J Med 1985;313:1557-1563.
4. Hamsten A, Blombäck M, Wiman B, Svensson J, Szamosi A, de Faire U, Mettinger L. Haemostatic function in myocardial infarction. Br Heart J 1986;55:58-66.
5. Hamsten A, Walldius G, Dahlén G, Johansson B, de Faire U. Serum lipoproteins and apolipoproteins in young male survivors of myocardial infarction. Atherosclerosis 1986;59:223-235.
6. Hamsten A, Efendic S, Walldius, Szamosi A, de Faire U. Glucose tolerance and insulin response to glucose in non-diabetic young male survivors of myocardial infarction. Am Heart J 1987;113:917-927.
7. Adult Treatment Panel II. National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Circulation 1994;89:1333-1445.
8. Havel RJ. Biology of cholesterol, lipoproteins and atherosclerosis. Clin Exp Hypertens 1989;11:887-900.
9. Gotto AM, Gorry GA, Thompson JR, Cole JS, Trost R, Yeshurun D, DeBakey ME. Relationship between plasma lipid concentrations and coronary artery disease in 496 patients. Circulation 1977;56:875-883.
10. Castelli WP, Doyle JT, Hamed CG, et al. HDL cholesterol and other lipids in coronary heart disease: The cooperative lipoprotein phenotyping study. Circulation 1977;55:767-772.
11. Schlant RC, Forman S, Stamler J, Canner PL. The natural history of coronary heart disease: Prognostic factors after recovery from myocardial infarction in 2,789 men. The 5-year findings of the Coronary Drug Project. Circulation 1982;66:401-414.
12. Pekkanen J, Linns, Heiss GM, Suchindran CM, Leon A, Rifkind BM, Tyroler HA. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990;322:1700-1707.
13. Lippel K, Tyroler H, Eder H, Gotto A, Vahouny G. Relationship of hypertriglyceridemia to atherosclerosis. Arteriosclerosis 1981;1:406-417.
14. Castelli WP. The triglyceride issue: A view from Framingham. Am Heart J 1986;112:432-437.
15. Nikkila M, Koivula T, Niemela K, Sisto T. High density lipoprotein cholesterol and triglycerides as marker of angiographically assessed coronary artery disease. Br Heart J 1990;63:78-81.
16. Brensike JF, Levy RI, Kelsey SF, et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis. Results of the NHLBI Type II Coronary Intervention Study. Circulation 1984;69:313-324.
17. MAAS investigators. Effect of simvastatin on coronary atheroma: The multicentre anti-antheroma study (MAAS). Lancet 1994;344:633-638.
18. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-1298.
19. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass. JAMA 1987;257:3233-3240.
20. Blankenhorn DH, Johnson RL, Nessim SA, Azen SP, Sanmarco ME, Selzer RH. The Cholesterol Lowering Atherosclerosis Study (CLAS). Design, methods, and baseline results. Controlled Clin Trials 1987;8:354-387.
21. Cashin-Hemphill L, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts: A 4-year follow-up. JAMA 1990;264:3013-3017.
22. Blankenhorn DH, Alaupovic P, Wickham E, Chin HP, Azen SP. Prediction of angiographie change in native human coronary arteries and aortocoronary bypass grafts: Lipid and nonlipid factors. Circulation 1990;81:470-476.
23. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990;264:3007-3012.
24. Watts GF, Lewis B, Brent JN, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St. Thomas' Atherosclerosis Regression Study (STARS). Lancet 1992;339:563-569.
25. Blankenhorn DH, Azen SP, Kramsch DM, et al. and the MARS Research Group. Coronary angiographic changes with lovastatin therapy; The Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 1993;119:969-976.
26. Hodis HN, Mack WJ, Azen SP, et al. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/ moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994;90:42-49.
27. Hodis HN, Mack WJ, Cashin-Hemphill L, Krauss RM. Differential effect of lipoproteins on coronary artery lesion progression (abstract). Circulation 1994;90:I532.
28. Hodis HN, Mack WJ, Knight-Gibson C, Alaupovic P. The role of triglyceride-rich lipoprotein families in the progression of coronary artery atherosclerotic lesions (abstr). J Am Coll Cardiol 1995, 195A.
29. Waters D, Higginson L, Gladstone P, Kimball B, Le May M, Boccuzzi SJ, Lesperance J. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994;89:959-968.
30. Buchwald H, Varco RL, Matts JP, et al. and the POSCH Group. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias. N Engl J Med 1990;323:946-955.
31. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischemic heart disease? Br Med J 1994;308:367-373.
32. Holme I. Relation of coronary heart disease incidence and total mortality to plasme cholesterol reduction in randomized trials: Use of meta analysis. Br Heart J 1993;69:S42-S47.
33. Brown BG, Zhao X-Q, Sacco DE, Albers JJ. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary artery disease. Circulation 1993;87:1781-1791.
34. Ericsson C-G, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. Angiographic assessment of the effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996;347:849-853.
35. de Faire U, Ericsson C-G, Grip L, Nilsson J, Svane B, Hamsten A. Secondary preventive potential of lipid-lowering agents - experience from the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). Eur Heart J 1996;17:37-42.
36. Jukema JE, Bruschke AVG, van Boven AJ, et al. on behalf of the REGRESS Study Group. Effect of lipid lowering by pravastatin on progression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995;91:2528-2540.
37. Blankenhorn DH, Hodis HN. Duff Memorial Lecture: Arterial imaging and atherosclerosis reversal. Arterioscler Thromb 1994;14:177-192.
38. Seiler C, Suter TM, Hess OM. Exercise-induced vasomotion of angiographically normal and stenotic coronary arteries improves after cholesterol-lowering drug therapy with bezafibrate. J Am Coll Cardiol 1995;26:1615-1622.
39. Leung WH, Lau CP, Wong CK. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation of hypercholesterolemic patients. Lancet 1993; 341:1496-1500.
40. Egashira K, Hirooka Y, Kai H, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994;89:2519-2524.
41. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-487.
42. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995;332:488-493.
43. Goldbourt U, Behar S, Reicher-Reiss H, et al. Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial). Am J Cardiol 1993;71:909-915.
44. Modan B, Assmann G, Bauer P, Kuller LH, Schoenberger J. Statement of the International Review and Advisory Board of the Bezafibrate Infarction Prevention study after its meeting on May 31, 1995, in Charlottesville, Va. Circulation 1995;92:1675.